- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01218243
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
May 18, 2013 updated by: Liu Zhishun, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
To evaluate efficacy of BL33 for mild and moderate benign prostatic hyperplasia(BPH).There are trials showing that electroacupuncture on BL33 for mild and moderate BPH is more effective than terazosin.
It could reduce the International Prostate Syndrome Score (IPSS) by 6.68±2.84(39.79%),lower
urinary symptoms bother of score(BS) and bladder residual urine, and increase maximum urinary flow rate.But the efficacy of BL33 has not been studied.
The objective of this study is to evaluate efficacy of BL32 for mild and moderate BPH by comparison with non-acupoint group.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
efficacy here means specific effect(or active ingredient) of the point BL33.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100053
- Guang'an Men Hospotal Affiliated to China Academy of Chinese Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- 50-70 years old
- Mild to moderate BPH evaluated by I-PSS
- Patients having urinary dysfunction more than 3 months
- Patients with stable life signs
- no use of α1 receptor blocker, 5α-reductase inhibitor or traditional Chinese medicine for over 1 week
- Volunteer to join this research and sign the written informed consent prior to receiving treatment
Exclusion Criteria:
- Urinary dysfunction caused by gonorrhea or urinary tract infection
- Oliguria and anuria caused by urinary calculi, prostate cancer, bladder tumor and acute/chronic renal failure
- Urinary dysfunction caused by neurogenic bladder, bladder neck fibrotic and urethral stricture
- Failure of invasive therapy for prostatic obstruction
- Injured local organs, muscle and nerve caused by pelvic operation or historical trauma
- Upper urinary obstruction and hydrocele combined with damaged renal function due to BPH diagnosed by B-ultrasound
- Patients who can't stick to treatment because of economic reason, far distance between home and the hospital or difficult walking etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: acupoint
Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz.
Stop turning up the current intensity when patients could not stand.
There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
|
For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle.
A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz.
Stop turning up the current intensity when patients could not stand.
5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
Other Names:
|
SHAM_COMPARATOR: non-acupoint
Take the place 2 cun far from BL33 on the outside horizontally as the non-point.
Needle on the non-point for 60-80mm with a 45°angle.
A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz.
Stop turning up the current intensity when patients could not stand.
5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
|
For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle.
A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz.
Stop turning up the current intensity when patients could not stand.
5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of IPSS at the 6th Week Compared With Baseline(Intention to Treat)
Time Frame: baseline and the 6th week
|
International Prostate Symptom Score (IPSS) Range:0-35(0 is best,35 is worst, ordinal),6 week mean minus baseline mean.And analysis for this outcome measure is based on ITT population.
|
baseline and the 6th week
|
Change of International Prostate Symptom Score(IPSS) at the 6th Week Compared With Baseline(Per-protocol).
Time Frame: baseline and the 6th week
|
International Prostate Symptom Score (IPSS) Range:0-35(0 is best,35 is worst, ordinal),6 week mean minus baseline mean.
And analysis for this outcome measure is based on per-protocol population.
|
baseline and the 6th week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Bladder Residual Urine at the 6th Week
Time Frame: baseline and the 6th week
|
Bladder residual urine was used to assess the bladder function, 6 week mean minus baseline mean
|
baseline and the 6th week
|
Change of Maximum Urinary Flow Rate(Qmax)at the 6th Week
Time Frame: baseline and the 6th week
|
Maximum urinary flow rate was used to assess the bladder function, 6 week mean minus baseline mean
|
baseline and the 6th week
|
Change of International Prostate Symptom Score (IPSS) at the 18th Week
Time Frame: baseline and the 18th week
|
International Prostate Symptom Score (IPSS) Range:0-35(0 is best,35 is worst, ordinal),18 week mean minus baseline mean.
|
baseline and the 18th week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wang Y, Liu B, Yu J, Wu J, Wang J, Liu Z. Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial. PLoS One. 2013 Apr 12;8(4):e59449. doi: 10.1371/journal.pone.0059449. Print 2013.
- Wang Y, Liu Z, Yu J, Ding Y, Liu X. Efficacy of electroacupuncture at Zhongliao point (BL33) for mild and moderate benign prostatic hyperplasia: study protocol for a randomized controlled trial. Trials. 2011 Sep 26;12:211. doi: 10.1186/1745-6215-12-211.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (ACTUAL)
March 1, 2012
Study Completion (ACTUAL)
May 1, 2012
Study Registration Dates
First Submitted
October 8, 2010
First Submitted That Met QC Criteria
October 8, 2010
First Posted (ESTIMATE)
October 11, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
May 27, 2013
Last Update Submitted That Met QC Criteria
May 18, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009S208
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia (BPH)
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Medi-Tate Ltd.CompletedBenign Prostatic Hyperplasia (BPH)Spain, Belgium, Italy, Switzerland, United Kingdom
-
GemVax & KaelCompletedBenign Prostatic Hyperplasia (BPH)Korea, Republic of
-
University of Kansas Medical CenterEnrolling by invitationBenign Prostatic Hyperplasia | BPHUnited States
-
Brooklyn Urology Research GroupAmerican Medical Systems; Richard Wolf Medical Instruments Corporation (RWMIC)CompletedBenign Prostatic Hyperplasia (BPH)United States
-
Daniel Stephan EngelerCompletedBenign Prostatic Hyperplasia (BPH)Switzerland
-
HistoSonics, Inc.WithdrawnBenign Prostatic Hyperplasia (BPH)
-
Watson PharmaceuticalsCompletedBenign Prostatic Hyperplasia (BPH)United States
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Lawson Health Research InstituteGyrus ACMI, Inc.CompletedBenign Prostatic Hyperplasia | BPHCanada
Clinical Trials on needle
-
Guang'anmen Hospital of China Academy of Chinese...Completed
-
University of California, San FranciscoBaylis Medical CompanyCompletedHeart DiseasesUnited States
-
Istituto Clinico HumanitasUnknownPancreatic Cancer | Neuroendocrine Tumors | GIST | Lymphadenopathies | Gastric Wall TumorItaly
-
Postgraduate Institute of Medical Education and...CompletedUpper Extremity Injury Trauma
-
Boston Scientific CorporationCompletedPancreatic Cystic LesionsUnited States, China, India
-
Philips HealthcareWithdrawnProstate CancerUnited States
-
Kyungpook National University HospitalRecruitingAnalgesia, EpiduralKorea, Republic of
-
Kyungpook National University HospitalCompletedDisk Herniated Lumbar | Spinal Stenosis LumbarKorea, Republic of
-
The University of Hong KongUnknown
-
University of ChicagoCook Group IncorporatedCompletedPancreatic CancerUnited States